Synapse - Works

Results (115372)

Outcomes and management of SARS-CoV2 omicron variant in recipients of hematopoietic cell transplantation (HCT) and CAR-T therapy

Meeting Abstract

Infante, M. S.; DeWolf, S.; Tamari, R.; Dahi, P. B.; Lee, Y. J.; Politikos, I.; Barker, J. N.; Babady, N. E.; Ramanathan, L.; Seo, S.; more...
Blood (2022)

Fulltext@MSK | Save

Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1

Meeting Abstract

Munshi, N. C.; Paiva, B.; Martin, T.; Usmani, S.; Lin, Y.; Schecter, J. M.; Jackson, C. C.; Madduri, D.; Zudaire, E.; Yeh, T. M.; more...
Blood (2022)

Fulltext@MSK | Save

Peripheral blast count at apheresis acts independent of disease burden as a risk factor for survival following tisagenlecleucel in children and young adults

Meeting Abstract

Fabrizio, V. A.; Miller, K.; Baggott, C.; Prabhu, S.; Pacenta, H.; Phillips, C. L.; Rossoff, J.; Stefanski, H. E.; Talano, J.; Moskop, A.; more...
Blood (2022)

Fulltext@MSK | Save

Predictors and implications of renal injury in large cell lymphoma patients receiving CD19 CAR T cell therapy

Meeting Abstract

Boardman, A. P.; Gutgarts, V.; Flynn, J. R.; Devlin, S. M.; Tomas, A. A.; Fein, J. A.; Slingerland, J.; Parascondola, A.; Lin, R. J.; Scordo, M.; more...
Blood (2022)

Fulltext@MSK | Save

Prognostic impact of comorbidities on outcomes of patients (pts) with relapsed or refractory large B-cell lymphoma (r/r LBCL) treated with chimeric antigen receptor T-cell therapy (CART)

Meeting Abstract

Greenbaum, U.; Hashmi, H.; Elsawy, M.; Kim, S.; Moskop, A.; Awan, F. T.; Farooq, U.; Ganguly, S.; Hematti, P.; Jain, M. D.; more...
Blood (2022)

Fulltext@MSK | Save

Interim phase I clinical data of FT819-101, a study of the first-ever, off-the-shelf, iPSC-derived TCR-less CD19 CAR T-cell therapy for patients with relapsed/refractory B-cell malignancies

Meeting Abstract

Mehta, A.; Farooq, U.; Chen, A.; McGuirk, J. P.; Ly, T.; Wong, L.; Cooley, S.; Valamehr, B.; Elstrom, R.; Chu, Y. W.; more...
Blood (2022)

Fulltext@MSK | Save

Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma

Meeting Abstract

Mailankody, S.; Matous, J. V.; Liedtke, M.; Sidana, S.; Oluwole, O. O.; Mohan, M.; Cruz, J. C.; Nath, R.; Anwer, F.; Rossi, A.; more...
Blood (2022)

Fulltext@MSK | Save

Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed/refractory multiple myeloma: Early experience from a phase I study

Meeting Abstract

Lesokhin, A. M.; Richter, J.; Trudel, S.; Cohen, A. D.; Spencer, A.; Forsberg, P. A.; Laubach, J. P.; Thomas, S. K.; Bahlis, N. J.; Costa, L. J.; more...
Blood (2022)

Fulltext@MSK | Save

A phase 1 first-in-human study of Abbv-383, a BCMA x CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma

Meeting Abstract

Voorhees, P. M.; D'Souza, A.; Weisel, K.; Hurd, D. D.; Teipel, R.; Chung, A.; Rodriguez, C.; Tuchman, S. A.; Korde, N.; Safah, H.; more...
Blood (2022)

Fulltext@MSK | Save

A phase 2 trial of colesevelam for lenalidomide-associated diarrhea

Meeting Abstract

Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
Blood (2022)

Fulltext@MSK | Save